- Home
- TWST vs IMVT Comparison
TWST vs IMVT Comparison
Compare TWST & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWST
- IMVT
- Stock Information
- Founded
- TWST 2013
- IMVT N/A
- Country
- TWST United States
- IMVT United States
- Employees
- TWST N/A
- IMVT N/A
- Industry
- TWST Biotechnology: Biological Products (No Diagnostic Substances)
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TWST Health Care
- IMVT Health Care
- Exchange
- TWST Nasdaq
- IMVT Nasdaq
- Market Cap
- TWST 3.1B
- IMVT 3.6B
- IPO Year
- TWST 2018
- IMVT N/A
- Fundamental
- Price
- TWST $52.74
- IMVT $22.29
- Analyst Decision
- TWST Buy
- IMVT Strong Buy
- Analyst Count
- TWST 10
- IMVT 11
- Target Price
- TWST $52.50
- IMVT $46.11
- AVG Volume (30 Days)
- TWST 773.9K
- IMVT 1.2M
- Earning Date
- TWST 02-03-2025
- IMVT 02-10-2025
- Dividend Yield
- TWST N/A
- IMVT N/A
- EPS Growth
- TWST N/A
- IMVT N/A
- EPS
- TWST N/A
- IMVT N/A
- Revenue
- TWST $330,189,000.00
- IMVT N/A
- Revenue This Year
- TWST $21.65
- IMVT N/A
- Revenue Next Year
- TWST $17.56
- IMVT N/A
- P/E Ratio
- TWST N/A
- IMVT N/A
- Revenue Growth
- TWST 25.85
- IMVT N/A
- 52 Week Low
- TWST $27.41
- IMVT $20.43
- 52 Week High
- TWST $60.90
- IMVT $39.55
- Technical
- Relative Strength Index (RSI)
- TWST 57.63
- IMVT 28.71
- Support Level
- TWST $45.30
- IMVT $21.48
- Resistance Level
- TWST $53.95
- IMVT $22.22
- Average True Range (ATR)
- TWST 3.48
- IMVT 1.00
- MACD
- TWST 0.28
- IMVT -0.11
- Stochastic Oscillator
- TWST 69.85
- IMVT 9.88
About TWST Twist Bioscience Corporation
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).